Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for the Treatment of Ulcerative Colitis, but Future Projections Reveal a Highly Evolving Market
March 22, 2024 10:14 ET
|
Spherix Global Insights
Exton, Pennsylvania, March 22, 2024 (GLOBE NEWSWIRE) -- The end of 2023 introduced several new treatment options for patients suffering from ulcerative colitis (UC). Among them is Eli Lilly’s Omvoh...